Characteristics and trends of PCSK9 inhibitor prescription fills in the United States-Reference-Cited by-同舟云学术

Characteristics and trends of PCSK9 inhibitor prescription fills in the United States

Published:2021-03 Issue:2 Volume:15 Page:332-338
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Attipoe-Dorcoo Sharon^ORCID,Yang Peter,Sperling Laurence,Loustalot Fleetwood,Thompson-Paul Angela M.,Gray Elizabeth B.,Park Soyoun^ORCID,Ritchey Matthew D.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference11 articles.

1. AHA_ASA. Cardiovascular Disease: A Costly Burden for America — Projections through 2035. vol. 2020: American Heart Association.

2. Management of Blood cholesterol;Alenghat;J Am Med Assoc,2019

3. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of Blood cholesterol: a report of the American College of Cardiology/American Heart association task force on clinical practice guidelines;Grundy;J Am Coll Cardiol,2018

4. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

5. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial;Ray;Lancet Diabetes Endocrinol,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25

2. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke;Frontiers in Pharmacology;2024-01-11

3. Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events;Pharmacology & Therapeutics;2023-10

4. Trends in Lipid-Lowering Prescriptions: Increasing Use of Guideline-Concordant Pharmacotherapies, U.S., 2017‒2022;American Journal of Preventive Medicine;2023-04

5. 14. Dyslipidemia;Chronic Disease Epidemiology, Prevention, and Control, 5th edition;2023-01